{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-429423","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-10-23T10:36:06+00:00","discovered_at":"2026-10-23T10:40:00.290457+00:00","generated_at":"2026-10-23T10:40:06.212171+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tango's vopimetostat+daraxonrasib shows 82% ORR in 2L/3L PDAC; Phase 3 planned, workforce cut 14%","bullets":["Phase 1/2: 82% ORR (18/22) in 2L/3L MTAP-deleted/RAS-mutant PDAC; median PFS not reached, 88% 9-month PFS, 100% DCR at Aug 20, 2026 cutoff.","Dose level 1 vopimetostat 200 mg + daraxonrasib 100 mg daily well tolerated: no DLTs, no Grade 4/5 TRAEs, Grade 3 TRAEs 40%; dose level 2 had 3 DLTs in 2 patients.","FDA-aligned Phase 3 in front-line MTAP-deleted PDAC to randomize 1:1 vopimetostat+daraxonrasib vs standard chemotherapy, dual primary endpoints ORR and PFS, starting 1H 2027.","Zoldonrasib combo in MTAP-deleted/KRAS G12D PDAC: 54% ORR (19/35), 61% 9-month PFS, 97% DCR; NSCLC daraxonrasib combo 80% ORR (4/5).","Board approved Oct 22 strategic reprioritization: focus on PRMT5/vopimetostat/TNG456, halt certain preclinical work, cut workforce ~14%, mostly research."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-429423","json":"https://secwatch.observer/filing/0001193125-26-429423.json","markdown":"https://secwatch.observer/filing/0001193125-26-429423.md","text":"https://secwatch.observer/filing/0001193125-26-429423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/0001193125-26-429423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-23T10:40:06.212171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}